AIMLogo.jpg
AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
19 sept. 2024 08h00 HE | AIM ImmunoTech Inc.
Preliminary finding of stable disease in two out of three patients at 6 months in the first subject cohort Combination of Ampligen and Imfinzi continues to be generally well-tolerated with no...
revive-therapeutics.png
Revive Therapeutics Announces Strategic Focus on Bucillamine for Infectious Diseases and Medical Countermeasures
18 sept. 2024 07h00 HE | Revive Therapeutics Ltd.
TORONTO, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
logo.jpg
ImCheck Receives FDA Fast Track Designation for ICT01 in Combination with Azacitidine and Venetoclax in First-Line Acute Myeloid Leukemia for Patients Unfit for Induction Chemotherapy Treatment
18 sept. 2024 05h00 HE | ImCheck Therapeutics SAS
ImCheck Receives FDA Fast Track Designation for ICT01in Combination with Azacitidine and Venetoclaxin First-Line Acute Myeloid Leukemiafor Patients Unfit for Induction Chemotherapy Treatment ICT01,...
Nader Sanai, MD
Ivy Brain Tumor Center’s Dr. Nader Sanai Named Arizona Bioscience Researcher of the Year
17 sept. 2024 11h00 HE | Ivy Brain Tumor Center
Phoenix, AZ, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Dr. Nader Sanai, Director of the Ivy Brain Tumor Center, Chief of Neurosurgical Oncology at Barrow Neurological Institute, and the Francis &...
RNAZ White background cropped.jpg
TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
17 sept. 2024 07h00 HE | TransCode Therapeutics, Inc.
TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
image1 (1).png
Evaxion reports convincing one-year data from phase 2 trial on AI-designed personalized cancer vaccine EVX-01
16 sept. 2024 07h00 HE | Evaxion Biotech
11 out of 16 patients had objective clinical responses, equaling a 69% Overall Response Rate15 out of the 16 patients had a reduction of their tumors (target lesions)79% of EVX-01’s vaccine targets...
23andMe_Logo_grey.png
23andMe Therapeutics Announces Positive In Vivo Results for 23ME-01473, a Dual-Mechanism ULBP6-Targeting Antibody Currently in a Phase 1 Trial
15 sept. 2024 03h00 HE | 23andMe, Inc.
23ME-01473 inhibited tumor growth in a patient-derived xenograft mouse model of non-small cell lung cancer Elevated levels of soluble and tumor-bound ULBP6 confirmed in squamous cell carcinomas and...
23andMe_Logo_grey.png
23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study
15 sept. 2024 03h00 HE | 23andMe, Inc.
23ME-00610 monotherapy demonstrates preliminary evidence of clinical benefit in clear-cell renal-cell carcinoma, with one confirmed partial response Higher tumor expression of CD200 and human...
AIMLogo.jpg
AIM ImmunoTech Announces that Analysis of AMP-518 Complete Clinical Patient Data Underscores Ampligen’s Potential to Improve the Post-COVID Condition of Fatigue
11 sept. 2024 09h00 HE | AIM ImmunoTech Inc.
OCALA, Fla., Sept. 11, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced that an analysis of the complete clinical patient data from the AMP-518 clinical...
logo 600X600.png
Clinical Trial Software Market Surges to US$ 2.3 Billion by 2031, Propelled by 14.3% CAGR, States CoherentMI
10 sept. 2024 11h01 HE | CMI
Burlingame, Sept. 10, 2024 (GLOBE NEWSWIRE) -- CoherentMI published a report, titled, Clinical Trial Software Market is estimated to value at US$ 0.9 Billion in the year 2024, and is anticipated to...